In merlin-deficient schwannomas, mammalian target of rapamycin complex 1 (mTORC1) is constitutively activated, and mTOR inhibitors such as rapamycin (sirolimus) and its rapalogs (e.g., everolimus) influence vestibular schwannoma cell proliferation [28,68,69,70]. This evidence concerns the gene NF2 and Vestibular schwannoma.